Publications by authors named "M Roupret"
Background And Objective: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives.
View Article and Find Full Text PDFCurrent epidemiological indicators reflect the prevalence of prostate-specific antigen (PSA) testing rather than the actual incidence of clinically significant prostate cancer. These indicators are also biased because of the variability of the PSA test. We therefore need to adopt new reliable criteria in causal epidemiological studies and screening programs.
View Article and Find Full Text PDFWe aim to enhance the reporting of complications in surgical operations by establishing a classification for patient complexity. Current comorbidity assessment tools are insufficient due to their reliance on physiological parameters. The proposed patient surgical class category (PSCC) aims to address these limitations and enhance results by incorporating relevant aspects of a patient's surgical history.
View Article and Find Full Text PDFArticle Synopsis
- Intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy occurs in 22% to 47%, prompting the need for effective intravesical chemotherapy, which remains underused due to safety and efficacy concerns.
- A systematic review analyzed 18 studies with 2,483 patients, finding that intravesical chemotherapy significantly lowered the risk of recurrence at 12 months (OR=0.46) and 24 months (OR=0.41) after surgery.
- The study highlighted a favorable safety profile for intravesical chemotherapy, showing only 9% minor and 0.9% major complications, while the optimal instillation methods require further investigation.